PURPOSE: Despite numerous breakthrough therapies, inoperable lung cancer still places a heavy burden on patients who might not be candidates for chemotherapy. To identify potential candidates for the newly emerging immunotherapy-based treatment paradigms, we explored the clinical and biologic factors affecting treatment decisions. METHODS: We retrospectively reviewed the records of patients diagnosed at our university-affiliated cancer centre between 1 January 2011 and 31 December 2013. Patient demographics, systemic treatment, and survival were examined. RESULTS: During the 3-year study period, 683 patients fitting the inclusion criteria were identified. First-line therapy was administered in 49.5% of patients; only 22.4% received further lines of therapy. The main reasons for withholding therapy were poor performance status [ps (43.2%)], rapidly deteriorating ps (31.9%), patient refusal of therapy (20.9%), and associated comorbidities (4%). Older age, the presence of brain metastasis at diagnosis, and non-small-cell histology were also associated with therapeutic restraint. Oncology referrals were infrequent in patients who did not receive therapy (32.2%). Older patients and those with a poor ps experienced superior survival when treatment was administered (hazard ratio: 0.25; 95% confidence interval: 0.16 to 0.38; and hazard ratio: 0.44; 95% confidence interval: 0.23 to 0.87 respectively; p < 0.001). CONCLUSIONS: Advanced lung cancer still poses a therapeutic challenge, with a high proportion of patients being deemed unfit for therapy. This issue cannot be resolved until appropriate measures are taken to ensure the inclusion of older patients and those with a relatively poor ps in large clinical trials. Immunotherapy might be interesting in this setting, given that it appears to be more tolerable. Another consequential undertaking would be the deployment of strategies to reduce wait times during the diagnostic process for patients with a high index of suspicion for lung cancer.
PURPOSE: Despite numerous breakthrough therapies, inoperable lung cancer still places a heavy burden on patients who might not be candidates for chemotherapy. To identify potential candidates for the newly emerging immunotherapy-based treatment paradigms, we explored the clinical and biologic factors affecting treatment decisions. METHODS: We retrospectively reviewed the records of patients diagnosed at our university-affiliated cancer centre between 1 January 2011 and 31 December 2013. Patient demographics, systemic treatment, and survival were examined. RESULTS: During the 3-year study period, 683 patients fitting the inclusion criteria were identified. First-line therapy was administered in 49.5% of patients; only 22.4% received further lines of therapy. The main reasons for withholding therapy were poor performance status [ps (43.2%)], rapidly deteriorating ps (31.9%), patient refusal of therapy (20.9%), and associated comorbidities (4%). Older age, the presence of brain metastasis at diagnosis, and non-small-cell histology were also associated with therapeutic restraint. Oncology referrals were infrequent in patients who did not receive therapy (32.2%). Older patients and those with a poor ps experienced superior survival when treatment was administered (hazard ratio: 0.25; 95% confidence interval: 0.16 to 0.38; and hazard ratio: 0.44; 95% confidence interval: 0.23 to 0.87 respectively; p < 0.001). CONCLUSIONS: Advanced lung cancer still poses a therapeutic challenge, with a high proportion of patients being deemed unfit for therapy. This issue cannot be resolved until appropriate measures are taken to ensure the inclusion of older patients and those with a relatively poor ps in large clinical trials. Immunotherapy might be interesting in this setting, given that it appears to be more tolerable. Another consequential undertaking would be the deployment of strategies to reduce wait times during the diagnostic process for patients with a high index of suspicion for lung cancer.
Authors: C Mascaux; M Paesmans; T Berghmans; F Branle; J J Lafitte; F Lemaitre; A P Meert; P Vermylen; J P Sculier Journal: Lung Cancer Date: 2000-10 Impact factor: 5.705
Authors: Elise Kaspi; Diane Frankel; Julien Guinde; Sophie Perrin; Sophie Laroumagne; Andrée Robaglia-Schlupp; Kevin Ostacolo; Karim Harhouri; Rachid Tazi-Mezalek; Joelle Micallef; Hervé Dutau; Pascale Tomasini; Annachiara De Sandre-Giovannoli; Nicolas Lévy; Pierre Cau; Philippe Astoul; Patrice Roll Journal: PLoS One Date: 2017-08-14 Impact factor: 3.240
Authors: Frances B Maguire; Cyllene R Morris; Arti Parikh-Patel; Rosemary D Cress; Theresa H M Keegan; Chin-Shang Li; Patrick S Lin; Kenneth W Kizer Journal: JNCI Cancer Spectr Date: 2019-04-04
Authors: Daniel Santa Mina; Stefanus J van Rooijen; Enrico M Minnella; Shabbir M H Alibhai; Priya Brahmbhatt; Susanne O Dalton; Chelsia Gillis; Michael P W Grocott; Doris Howell; Ian M Randall; Catherine M Sabiston; Julie K Silver; Gerrit Slooter; Malcolm West; Sandy Jack; Franco Carli Journal: Front Oncol Date: 2021-01-11 Impact factor: 6.244
Authors: Ajeet Gajra; Nagla Abdel Karim; Deborah A Mulford; Liza Cosca Villaruz; Marc Ryan Matrana; Haythem Y Ali; Edgardo S Santos; Tymara Berry; Teng Jin Ong; Alexandra Sanford; Katayoun Amiri; David R Spigel Journal: Front Oncol Date: 2018-07-24 Impact factor: 6.244